Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

Exclusion Criteria

• •1. Unable to follow the treatment observation process required by the trial;
• •2. Genetic diseases, chromosomal abnormalities, and genetic deficiency that clearly cause premature ovarian insufficiency/premature ovarian failure;
• •3. With breast, uterine, ovarian tumors, or any other benign or malignant tumors;
• •4. Allergic history to drugs or any other things;
• •5. Presence of genetic disorders such as Turner's syndrome, congenital malformations of the reproductive organs.
• •6. Have undergone ovariectomy or have organic gynaecological diseases.
• •7. Presence of other gynaecological endocrine diseases such as polycystic ovary syndrome.
• •8. Severe functional impairment of vital organs.
• •9. High risk factors for venous thromboembolism and abnormalities in coagulation mechanisms.
• •10. Attending doctor considers inappropriate to take part in.